Kaleido differentiated itself through its novel approach to activating rather than inhibiting microbiome function. Founded by Flagship Pioneering in stealth mode (2015–2017) with an experienced management team and expanded pipeline, the company went public on NASDAQ in 2019 but ultimately ceased operations.
Cyborg Score Rationale
The company is defunct as of 2025. While it raised $165M across three funding rounds and achieved NASDAQ listing, it failed to advance therapies through clinical development successfully or secure continued investor confidence.